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Abstract 
Infection with the human papillomavirus (HPV) causes precursor intraepithelial 
lesions in women which may lead to the development of cervical cancer. There are 
several HPV types which show a variable distribution pattern worldwide. Therefore, 
identifying the prevalence of cancer-associated HPV types is important for the 
prevention of cervical cancer. In the current study, 627 cervical samples from 
individual women were collected by primary care clinics in Greece. The majority of 
women (70.17%) presented abnormal cytology as indicated by their Pap Test smear. 
Samples were sent to our laboratories for the detection of HPV by DNA analysis, 
PCR and reverse hybridization using HPV genotype-specific probes. Then, the 
prevalence of 28 different genotypes was estimated. Approximately 70% of all 
samples were infected with at least one HPV type. The most prevalent high risk (HR) 
HPV types associated with the development of cervical cancer were HPV types 16, 31 
and 51. Prevalence of HPV types, as well as appearance of them as a single or 
multiple infection were also studied in samples with normal and abnormal cytology. 
Our analysis showed that infected women with normal cytology in our study 
population tend to have single HPV infections. In contrast, those with abnormal 
cytological phenotype tend to have multiple infections of HR HPV types. 
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Abbreviations:  
HPV: Human Papillomavirus  
HR:  High Risk 
MR: Moderate Risk  
LR: Low Risk  
SILs: Squamous Intraepithelial Lesions   
ASCUS: Atypical Squamous Cells of Undetermined Significance  
LGSILs: Low-grade Squamous Intraepithelial Lesions  
HGSILs: High-grade Squamous Intraepithelial   
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Introduction 
The human papillomavirus (HPV) 
infection is one of the most common 
sexually transmissible infections in the 
world. More than 120 different HPV 
types have been catalogued and more 
than 40 are known to infect the 
epithelium of the anogenital tract and 
other mucosal areas of the body (de 
Villiers et al., 2004). Based on their 
association with cervical cancer and 
precursor lesions, HPVs can be 
classified as high (HR), moderate 
(MR) or low (LR) oncogenic risk 
according to their involvement in the 
genesis of benign or malignant 
conditions (Munoz et al., 2003). 
Among them, at least 16 HPV types 
are considered as high risk HPV and 
are strongly associated with the 
progression of cervical lesions and 
invasive cancer. HR HPV include 16, 
18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 
58, 59, 68, 73 and 82 types. MR HPV 
types 26, 53 and 66 are less frequently 
found in cancers but are often detected 
in squamous intraepithelial lesions 
(SILs). Finally, LR HPV types (6, 11, 
40, 42, 43, 44, 54, 55, 69, 70, 71 and 
74) are occasionally found in cervical 
carcinomas (Bernard et al., 2010). 
However, two of them, HPV type 6 
and HPV type 11 are associated with 
low-grade cervical cell abnormalities 
and laryngeal papillomas (Quiney et 
al., 1989). Recent studies demonstrate 
that more than 90% of genital warts are 
caused by these low-risk HPV types 
(Lacey, 2005). 
There are several studies indicating the 
prevalence of HPV types in different 
regions around the world (Bosch et al., 
2008; Clifford et al., 2005b). However, 
the frequency of HPV types may vary 
according to age, geographic, 
demographic and clinical-pathological 
factors (Clifford et al., 2005a; Li et al., 
2011). Focusing on cytological 
phenotype, Centers for Disease Control 
and Prevention (CDC) indicates that 
HPV infects the cutaneous epithelium 
which may lead to cervical cell 
abnormalities. HPV infection may be 
the result of a single type (single 
infection) or more than one type of the 
virus (multiple infections). Multiple 
infections seem to play an important 
role in the progression of cervical 
cancer and are detected in high 
frequency in cervical carcinomas 
(Huang et al., 2004). 
Considering the need to prevent HPV 
infection, it is essential to identify the 
prevalence of cancer-associated 
genotypes. Among Greek population, 
the prevalence of HPV in women is 
high, with HPV infection being quite 
common especially in younger ages 
(Papachristou et al., 2009). HR HPV 
type 16 seems to be the most prevalent 
in Southern Greece, detected either as 
a single or a multiple infection 
(Stamataki et al., 2010). Here, we 
studied the prevalence of HPV types in 
a cohort of Greek women and 
attempted to correlate single or 
multiple HPV infections with their 
cytological phenotype. 
 
Materials and Methods 
Samples 
Cervical samples (n=627) from 
individual women ages 16-66 having 
their annual check-up, cervical 
screening or gynaecological exam 
were routinely collected by medical 
doctors-gynaecologists in primary care 
clinics. Cervical samples were 
collected using ThinPrep Pap Test 
(Hologic), either with a plastic spatula 
for adequate sampling from the 
ectocervix or an endocervical brush 
device. Samples were rinsed into 
sterile ThinPrep bottles containing 
PreservCyt solution and sent to the 
laboratories of Biohellenika for HPV 
DNA testing. Each cervical sample 
obtained a code upon arrival in our 
labs. Samples included in the study 
were collected from 2009 to 2015. All 
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women were informed by their 
gynaecologists that the results of the 
DNA test may be used for a retrograde 
statistical analysis of HPV prevalence 
in Greece. Experimental data were 
handled according to the regulations of 
the Hellenic Data Protection Authority. 
All experiments were performed in 
compliance with relevant laws and 
institutional guidelines and in 
accordance with the ethical standards 
of the Declaration of Helsinki. 
In clinical practice, women are mainly 
subjected to a DNA test for HPV when 
there are indications of cytological 
abnormalities detected by either a Pap 
test or a histological analysis. To this 
end, Pap results were classified 
according to the most severe diagnosis 
as negative for intraepithelial lesion or 
malignancy, Atypical Squamous Cells 
of Undetermined Significance 
(ASCUS), Low-Grade Squamous 
Intraepithelial Lesion (LGSIL) and 
High-Grade Squamous Intraepithelial 
Lesion (HGSIL) (Solomon et al., 
2002). For study purposes, ASCUS, 
LGSILs and HGSILs were considered 
as abnormal cytology. Thus, cervical 
samples were categorized into two 
groups, according to their cytological 
phenotype. Group 1 comprises of 440 
samples from women having abnormal 
cytology and Group 2 consists of 187 
samples from women that presented 
normal cytology according to their Pap 
Test. Furthermore, infected samples 
were divided into groups harbouring 
either single or multiple HPV 
infections. In single infected samples, 
only one type of the virus was 
detected. On the other hand, up to 7 
HPV types were detected 
simultaneously in samples with 
multiple infections. 
 
Sample handling and DNA isolation 
All samples were handled under sterile 
conditions. Experimental procedures 
were performed in a cleanroom. DNA 
was isolated from each sample using 
the Nucleospin Tissue Kit (Macherey-
Nagel), according to the 
manufacturer’s instructions. DNA 
concentration was measured using the 
Nanodrop Spectophotometer. 
 
Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was 
performed using the INNO-Lipa HPV 
Genotyping Extra Amp Kit 
(Innogenetics). With this PCR-based 
amplification kit, 28 different 
genotypes of the human 
papillomavirus are identified. 
Detection is performed using the 
SPF10 primers which amplify a 65bp 
region in the conserved L1 region of 
the HPV genome. An additional set of 
primers for the amplification of the 
human HLA-DPB1 reference gene is 
contained in the reaction mix to 
monitor sample quality and extraction. 
 
Reverse Hybridization 
PCR products were reverse-hybridized 
using the INNO-Lipa HPV Genotyping 
Extra Kit (Innogenetics) which detects 
HR, MR and LR HPV genotypes. The 
reverse-hybridization assay offers a 
platform for highly specific probe 
hybridization. All DNA probes are 
immobilized as parallel lines on 
membrane strips, on which 28 HPV 
sequence-specific DNA probe lines 
and 4 control lines are fixed. HPV 
types 44/51 and 69/71 are detected by 
a single DNA probe, respectively. 
Control lines are: a) the Conjugate 
control which controls the addition of 
reactive Conjugate and Substrate 
solution during the detection 
procedure, b) the human DNA control 
line, which is the fragment of the 
human HLA-DPB1 reference gene, c) 
two HPV control lines. PCR products 
(10ul) were mixed with equal volume 
of Denaturation solution for 5min at 
room temperature. Then, Hybridization 
solution (2ml) was added and samples 
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were hybridized to the immobilized 
probes at 49
o
C for 1h. Probes were 
washed and incubated with 
streptavidin-conjugated alkaline 
phosphatase for 30min at room 
temperature. Finally, HPV-specific 
hybrids were detected using 
NBT/BCIP chromogen. According to 
the manufacturer, a sample was 
considered HPV positive when the 
human DNA control was detected and 
at least one of the type-specific lines 
and one of the HPV control lines were 
positive. Moreover, all HPV types 
were scored as negative in the sample 
if the type-specific line pattern 
(columns of the Interpretation chart) 
was a subset of the full line pattern 
observed on the strip. When the human 
DNA control line was detected but no 
HPV specific line was positive, the 
sample was considered as negative.  
 
Validation of the results 
The results of the INNO-Lipa HPV 
Genotyping Extra Amp Kit were 
validated using the PapilloCheck kit 
(GreinerBioone) for HPV DNA typing. 
Twenty samples of our group 
population were randomly selected and 
used to perform the microarray method 
according to the manufacturer’s 
instructions.  
 
Statistical Analysis 
Statistical analysis was performed 
using the SPSS software. The type-
specific HPV prevalence and 95% 
Confidence Interval (CI) were 
estimated for all HPV types detected 
within our study population 
(Supplementary Table 1). A two tailed 
z-test of a single proportion was used 
to discover whether statistical 
difference exists between the 
proportion detected from multiple 
infections rather than that from single 
infections. The analysis was performed 
either for infected samples with either 
abnormal/normal cytology (Table 2) or 
any HR HPV type detected in our 
study population (Supplementary 
Table 2). The null hypothesis was that 
the occurrence of any of the two type 
of infections is random (50%-50%, 
Ho: p=0.5, H1≠0.5). If the z-value of 
the test was found to be either less than 
-1.96 or greater than 1.96 (z<-1.96 or 
z>1.96) the statistical difference (alpha 
= 0.05) between the two proportions is 
significant and the null hypothesis is 
rejected. In the opposite case, the null 
hypothesis stands and no significant 
difference is reported. 
 
Results 
Detection of HPV infections 
Consecutive cervical samples (n=627) 
were collected. Pap smear reported that 
440 samples had abnormal cytological 
findings (70.17% of total population) 
while 187 samples (29.82% of total 
population) displayed normal cytology. 
Among those with abnormal cytology, 
290 cervical samples (46.25% of total 
population) presented ASCUS, 122 
samples (19.46% of total population) 
had LGSIL and 28 samples (4.46% of 
total population) presented HGSIL in 
the Pap smear. Samples were then 
routinely tested for HPV infection. 
Samples from 439 women (~70% of 
total population) were found to be 
positive for infection with various 
HPV types, while 188 women were 
negative for any HPV infection (~30% 
of total population). Further analysis 
indicated that 325 samples (ASCUS: 
n=208, LGSIL: n=98, HGSIL: n=19) 
from those with abnormal cytology 
(n=440) harboured HPV infections, 
indicating the high correlation between 
epithelial lesions and HPV infection 
(Table 1). 
  
Prevalence of HPV types 
The prevalence of HR, MR and LR 
HPV types in infected women of our 
study population (n=439) was then 
analyzed. The prevalence of any HPV  
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Table 1: Cytology and HPV infection of total samples. Table shows the number of 
total cervical samples classified according to their cytology and HPV infection. 
HPV infection Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative
n 208 82 98 24 19 9 114 73 439 188
ASCUS LGSIL HGSIL
122Total samples 
per category
290
Total samples
440
187 627
Abnormal Cytology
Normal Cytology
28
 
Table 2: Single/Multiple Infections of HPV infected samples. Table shows the 
number of infected cervical samples detected with either single or multiple infections, 
according to their cytology. It also shows the statistical score (p-value); this indicates 
whether a statistical difference exists between the proportion of  single vs multiple 
infection in Groups 1 and 2 (ns: non significant, **: p-value <0.01). 
Infection Single Multiple p-value Single Multiple p-value
n 170 155 74 40
Total
Group 2 (Normal Cytology)
325 114
Group 1 (Abnormal Cytology)
ns **
type is shown in Figure 1. HPV types 
16, 51 and 31 were the most common 
HR types detected in these samples. 
Type 16 appeared in 22.1% (95%CI: 
21.5-22.7), type 31 in 18% 
(95%CI:17.4-18.6) and type 51 in 
17.5% (95%CI: 17-18.1) of infected 
samples. Moreover, HPV types 53 and 
66 were the most prevalent MR types, 
being detected in 13.9% (95%CI: 13.4-
14.4) and 12.5% (95%CI: 12-13)  of all 
infected women, respectively. Finally, 
types 44/55, 74 and 6 were the most 
common LR HPV types appearing in 
6.4% (95%CI: 6-6.8), 5% (95%CI: 4.7-
5.3)  and 5% (95%CI: 4.7-5.3)  of 
infected samples (Figure 1, 
Supplementary Table 1). Validation of 
the results obtained with the INNO-
Lipa HPV Genotyping Extra Kit was 
performed in twenty randomly selected 
samples using a secondary screening 
method (PapilloCheck kit). 
 
Prevalence of HPV types according 
to their cytology 
Infected samples were also analyzed 
according to their cytology. They were 
categorized in Group 1, samples from 
women with abnormal cytology 
(n=325) and Group 2, samples from 
women with normal cytology (n=114). 
170 samples (52.3%) belonging to 
Group 1, harboured a single HPV 
infection and 155 samples (47.7%) 
multiple HPV infections. On the other 
hand, 74 samples (64.9%) belonging to 
Group 2 were detected with a single 
HPV infection and only 40 samples 
(35.1%) with multiple HPV infections 
(Table 2). The results of a single 
proportion two tailed z-test showed 
that statistical difference (p<0.01) 
exists only between the proportions of 
Group 2 (women with normal 
cytology), indicating that women with 
normal cytology in our study 
population tend to harbour single HPV 
infections.  
We also analyzed the prevalence of 
any HPV type in infected samples 
(n=439) according to their cytology. 
The most prevalent HR HPV types in 
samples from Group 1 (abnormal 
cytology) were 16, 51 and 31; in 
samples belonging to Group 2 (normal 
cytology) HPV types 16, 31 and 56 
were mainly detected (Supplementary 
Figures 1 and 2). Interestingly, the 
most prevalent HR HPV types in 
Group 1 tend to appear within the 
context of multiple infections. Single  
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Figure 1: Prevalence of HPV genotypes in a population of Greece. Figure shows the 
prevalence (%) of High risk (HR), moderate risk (MR) and low risk (LR) HPV types in 
infected women.  
and multiple infections of the most 
prevalent HR HPV types were then 
studied for infected samples of Group 
1 (Supplementary Figure 1). Two 
tailed z-test of a single proportion 
showed that for 5 HPV types (HPV31, 
18, 39, 73, 33), statistical difference 
between the two proportions is 
significant (p< 0.05); in all cases 
multiple infections are detected more 
often than single ones (Supplementary 
Table 2). 
 
Discussion 
HPV infections are fairly common 
nowadays. Genetic studies have shown 
the prevalence of various HPV types 
worldwide, indicating that HPV 
infection correlates with the age and 
the sexual behavior of the individual 
across different geographical regions 
(Smith et al., 2008). In the present 
study, HPV types in consecutive 
samples tested in our laboratories 
(n=627) were retrospectively 
statistically analyzed. As expected, a 
high percentage of these samples were 
positive for HPV infection. Several 
women are preventively tested for 
HPV infection. However, clinical 
doctors tend to propose a DNA test for 
HPV mainly when cytological 
abnormalities are detected. In our case, 
70.17% of all samples presented 
cytological abnormalities. This may 
explain the high ratio of HPV infected 
samples in our study population. Our 
results are in agreement with other 
population studies which also indicate 
a high prevalence of HPV infection in 
women with abnormal cytological 
findings in Greece (Argyri et al., 2013; 
Stamataki et al., 2010). 
We also observed that several samples 
with abnormal cytology, were negative 
for HPV infection. This suggests that 
an abnormal cytological phenotype 
may not be solely associated with an 
HPV infection. However, we cannot 
exclude the possibility that this 
represents a limitation of our method 
which may fail to detect viral loads in 
some samples. Additionally, several 
samples with normal cytology were 
also scored as positive for HPV 
infection. In these samples, it is 
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possible that low concentration of the 
virus can be detected by DNA analysis 
earlier than the appearance of  
epithelial lesions (Liaw et al., 1999). 
We also studied the prevalence of the 
different HPV types and found that the 
high risk types 16, 51 and 31 were 
more often detected in this study 
population. The results are in 
agreement with similar studies, 
indicating the high prevalence of these 
types in Southern European countries 
(Castellsague et al., 2012; Giorgi Rossi 
et al., 2010; Pista et al., 2011a). HPV 
type 16 is the most prevalent type 
worldwide, an observation which was 
also reported in a recent cross-sectional 
study carried out in Greece (Agorastos 
et al., 2014). It should be noted that 
over 70% of all cervical cancer cases 
are related to the presence of HPV 
types 16 and 18. Based on these 
observations highly effective vaccines 
against this type have been designed 
(Joura et al., 2007; Paavonen et al., 
2007) and a large vaccination program 
has been launched in order to prevent 
cervical cancer. 
Furthermore, we studied the 
prevalence of single and multiple HPV 
infections in infected women with 
abnormal or normal cytology. In 
agreement with previous observations 
(Dickson et al., 2014; Pista et al., 
2011b), we found a tendency for 
multiple HR HPV infections in 
samples with abnormal cytological 
findings. Specifically, our results 
indicate a statistically significant 
detection of HR HPV 31 within 
multiple infections. Similar tendencies 
were found for other HR HPV types 
(Supplementary Table 2). However, 
more samples should be tested before 
drawing a concrete conclusion for the 
participation of these genotypes in 
multiple infections. Concerning 
infected women with normal cytology, 
we found a statistically significant 
difference towards single HPV 
infections (p<0.05). Therefore, a 
normal phenotype may gradually 
transit to a more severe cytological 
status when there are multiple HPV 
infections. 
In conclusion, here we show that single 
HPV infections are often detected in 
Greek women with normal cytology. 
Also, HR HPV genotypes are mainly 
detected within multiple infections in 
women with abnormal cytology. This 
suggests that women with single HPV 
infections are more likely to present 
epithelial lesions associated with 
cervical cancer, if they are infected 
with more than one type of the virus. 
Thus, we propose that regular HPV 
DNA testing in all ages, regardless the 
result of the Pap test, public 
information about the consequences of 
HPV infection and promotion of the 
prophylactic methods may help to 
reduce HPV prevalence within the 
Greek population.  
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Supplementary Materials  
 
 
Supplementary Figure 1: Prevalence of HPV genotypes in samples with abnormal 
cytology. Figure shows the prevalence (%) of High risk (HR), moderate risk (MR) 
and low risk (LR) HPV types in infected women with abnormal cytology. Columns 
also indicate the participation of each genotype in single or multiple 
 
 
Supplementary Figure 2: Prevalence of HPV genotypes in samples with normal 
cytology. Figure shows the prevalence (%) of High risk (HR), moderate risk (MR) 
and low risk (LR) HPV types in infected women with normal cytology. Columns also 
indicate the participation of each genotype in single or multiple infections. 
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Supplementary Table 1 
HPV Type 
Infected Samples CI 
n % low high 
HR 
16 97 22,096 21,462 22,729 
31 79 17,995 17,409 18,582 
51 77 17,540 16,959 18,121 
56 43 9,795 9,341 10,249 
58 39 8,884 8,449 9,318 
18 36 8,200 7,781 8,619 
52 23 5,239 4,899 5,579 
33 19 4,328 4,017 4,639 
68 19 4,328 4,017 4,639 
39 18 4,100 3,797 4,403 
45 15 3,417 3,139 3,694 
73 13 2,961 2,702 3,220 
59 12 2,733 2,484 2,983 
35 7 1,595 1,403 1,786 
82 7 1,595 1,403 1,786 
MR 
53 61 13,895 13,367 14,423 
66 55 12,528 12,023 13,034 
26 9 2,050 1,834 2,267 
LR 
44/55 28 6,378 6,005 6,751 
6 22 5,011 4,678 5,345 
74 22 5,011 4,678 5,345 
69/71 15 3,417 3,139 3,694 
54 13 2,961 2,702 3,220 
42 12 2,733 2,484 2,983 
70 7 1,595 1,403 1,786 
40 6 1,367 1,189 1,544 
11 5 1,139 0,977 1,301 
43 3 0,683 0,558 0,809 
      
  762    
      
Supplementary Table 1: Prevalence of HPV genotypes 
in Greek women. Table shows the number (n) and 
prevalence (%) of HPV types detected in infected 
samples (n=439). It also shows the range of values for a 
95% confidence interval (CI) of our analysis. 
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Supplementary Table 2 
HPV type n 
Single 
Infection 
Multiple 
Infection 
z-value p-value 
HR 
16 67 26 41 -1,7883 ns 
51 65 25 40 -1,8226 ns 
31 60 15 45 -3,4641 *** 
18 28 8 20 -2,0815 * 
56 28 11 17 -1,1384 ns 
58 26 6 20 -1,9085 ns 
52 20 6 14 -1,6609 ns 
39 16 2 14 -2,4 * 
73 16 1 15 -2,634 ** 
33 15 3 12 -1,9926 * 
45 13 4 9 -1,2943 ns 
68 12 3 9 -1,549 ns 
59 8 2 6 -1,2649 ns 
35 6 1 5 -1,3587 ns 
82 4 1 3 -0,8944 ns 
       
Supplementary Table 2: Detection of HR HVP types in samples with 
abnormal cytology. Table shows the number (n) of HR HPV infected 
samples harbouring single or multiple infections. It also shows the z-
value and statistical score (p-value); this indicates whether a statistical 
difference exists between the proportion of single vs multiple infection 
of a HR HPV type (ns: non significant,  *: p <0.05, **: p<0.01, ***: 
p<0.001). 
 
 
 
